|
|
|
|
ADMERITOX is a drug development
consultancy, dedicated to providing high-quality support to the clients' preclinical
projects regarding:
- development strategy,
- study monitoring,
- data assessment and presentation
ADMERITOX is owned by Ria Vos, PhD
Ria has 20 years of experience in preclinical development of pharmaceuticals, comprising
toxicology, ADME, and safety pharmacology. Her expertise ranges from the design of
the program, to supervision, monitoring and reporting of the various studies, and
the writing of the preclinical parts of regulatory documents such as the Common Technical
Document. She has had the opportunity to contribute to meetings with the FDA and
European regulatory agencies.
After a PhD in Toxicology and Biochemistry (Wageningen University, The Netherlands),
Ria Vos joined the pharmaceutical company Organon in The Netherlands. She was manager
of the ADME group, study director of ADME studies and a member of various Development
Project Teams for 7 years. She then became manager of the preclinical International
Project Team Representatives, where she supervised the preparation and implementation
of development strategies (toxicology, ADME, safety pharmacology), safety evaluations
prior to the start of "first in human" studies, and contributions to position
papers and regulatory documents. After 5 years in that position, she moved to France
for family reasons. She started ADMERITOX early 2004.
You can download and print the content of this website as admeritox.doc or admeritox.pdf
|
|
|
|
